27 Jan 2022 , 01:25 PM
Result date: 28th January, 2022
Recommendation: Buy
Target price: Rs5,450
(Source: IIFL Research)
Dr. Reddy’s Laboratories (Dr. Reddy’s) is all set to report 14% YoY growth in revenue to Rs56,071 million. Net profit could increase 24% to Rs7,644 million on a YoY basis.
The company’s US business is expected to post a robust performance on QoQ basis, amid doubling of market share in Vascepa from ~4.5% in Q2 to ~9% in Q3. This, coupled with the full quarter impact of the Revlimid Canada opportunity (launched in early September 2021), could drive ~3% QoQ growth in Dr. Reddy’s US sales for the quarter. Revenue of domestic business could get a leg up from sales of Sputnik.
Important management insights to watch out for:
Rs. Million | December 2021 estimates | YoY change | QoQ change |
Revenue | 56,071 | 14% | (1%) |
EBITDA | 12,612 | 12% | 3% |
PAT | 7,644 | 24% | (8%) |
Source: Company, IIFL Research
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.